A patient with amyotrophic lateral sclerosis (ALS), a progressive and often fatal neurodegenerative disease, showed significant improvement in their condition one year after receiving an experimental RNA-based therapy. This treatment was specifically designed to target a rare genetic mutation in the CHCHD10 gene, which is associated with a small subset of ALS cases. The patient’s blood levels of light chain neurofilaments, a biomarker that indicates the rate of nerve cell damage, dropped by about 50% compared to their initial levels. Additionally, the patient continued to work as a doctor after beginning the treatment, suggesting that their condition had stabilized or even improved. ALS is characterized by the gradual degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, speech difficulties, and eventually, paralysis. Most patients face significant challenges with breathing and typically live two to five years after diagnosis. While there is no cure for ALS, researchers have been exploring new treatment options, including antisense oligonucleotide therapies. These therapies use specially designed strands of genetic material to interfere with the production of harmful proteins caused by specific genetic mutations. Unlike traditional gene therapies, they target the RNA rather than the DNA, aiming to reduce the amount of faulty protein produced. The treatment in question was developed by researchers at the Mayo Clinic in Jacksonville and was administered to the first patient with a mutation in the CHCHD10 gene. This mutation affects a protein crucial for mitochondrial function, and its disruption can lead to the degeneration of motor neurons. The patient received a series of intrathecal injections—delivered directly into the spinal fluid—over a period of about a year. The results, published in the journal Med, showed a significant drop in neurofilament levels, improved scores on the ALS Functional Rating Scale, and increased vital capacity, which measures lung function. Importantly, the patient experienced no serious side effects, and their cognitive function and quality of life remained stable. While the results are encouraging, the researchers caution that more studies are needed to confirm the treatment’s effectiveness. The patient’s improvement could be due to the therapy, but some ALS patients occasionally experience temporary symptom relief without treatment. Nevertheless, the fact that the drug was developed, tested in animals, and then administered to a patient before their condition worsened is considered a major achievement. The treatment is now being tested in at least eight other patients with the same mutation as part of an ongoing clinical trial. Researchers plan to monitor the first patient closely and may increase their dose in the future. As with most antisense therapies, continuous treatment is necessary to maintain the drug’s effectiveness in the body.